Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$113.74 USD

113.74
2,577,623

+0.65 (0.58%)

Updated Sep 27, 2024 11:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck's Ebola Vaccine Ervebo Gets Approval in United States

by Zacks Equity Research

FDA grants approval to Merck's (MRK) Ervebo vaccine for active immunization of individuals 18 years and above to protect against Ebola virus disease caused by Zaire Ebola virus.

Seattle Genetics Gets Speedy FDA Nod for Bladder Cancer Drug

by Zacks Equity Research

The FDA grants accelerated nod to Seattle Genetics' (SGEN) Padcev to treat urothelial cancer. It also assigns Breakthrough Therapy tag to tucatinib for advanced/metastatic HER2-positive breast cancer.

Pentair Shuts Down Aquaculture Business, Divests Vaki Unit

by Zacks Equity Research

Pentair (PNR) divests Vaki business unit to focus on the residential and commercial pool segments.

Swayta Shah headshot

Buy These 5 Stocks With Upgraded Broker Ratings for 2020

by Swayta Shah

When a broker upgrades a stock, you can rely on their judgment. Nonetheless, you should also take into account few other factors to ensure steady returns.

FDA Panel Laps Up Merck's Keytruda & Lynparza for New Maladies

by Zacks Equity Research

The FDA's ODAC votes in favor of Merck's (MRK) Keytruda for non-muscle invasive bladder cancer. The panel also backs Lynparza as a first-line maintenance monotherapy for pancreatic cancer.

ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway

by Zacks Equity Research

FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine. Shares up.

Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020

by Zacks Equity Research

Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.

Novartis' Asthma Candidate Fails in LUSTER Phase III Studies

by Zacks Equity Research

Novartis' (NVS) asthma candidate, fevipiprant, fails to meet endpoint in the phase III LUSTER studies.

Pfizer's Xtandi Gets FDA Nod for Expanded Patient Group

by Zacks Equity Research

With data from the ARCHES study approved to be included in the label of Pfizer's (PFE) Xtandi, it can treat a broader prostate cancer patient population.

Pfizer Gets CHMP Nod for Vyndaqel Label Expansion in Europe

by Zacks Equity Research

Pfizer (PFE) receives a positive CHMP opinion recommending approval for once-daily Vyndaqel (61mg) oral capsule to treat hereditary transthyretin amyloid cardiomyopathy in adult patients.

Roche's (RHHBY) Tecentriq Combo Succeeds in Melanoma Study

by Zacks Equity Research

Roche's (RHHBY) Tecentriq in combination with Cotellic and Zelboraf meets primary goal.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study

by Kinjel Shah

This week two deals grab headlines in the pharma space. Merck (MRK) offers to buy ArQule for $2.7 billion while Sanofi (SNY) signs a definitive deal to purchase Synthorx for $2.5 billion

AstraZeneca's Imfinzi Gets China Nod for Stage III NSCLC

by Zacks Equity Research

AstraZeneca's (AZN) Imfinzi becomes the first immunotherapy to receive approval in China for treating unresectable, stage III NSCLC, which has not progressed following chemotherapy and radiation therapy.

Sanofi, Regeneron to Amend Agreement for Kevzara & Praulent

by Zacks Equity Research

Sanofi (SNY) intends to amend its antibody collaboration with Regeneron related to Kevzara and Praulent into a royalty-based agreement. Agreement terms for Dupixent to remain intact.

Roche's (RHHBY) sBLA for Asthma Drug Xolair Accepted by FDA

by Zacks Equity Research

The FDA accepts Roche's (RHHBY) allergic asthma drug Xolair's sBLA for the treatment of nasal polyps in adult patients aged 18 years or above with inadequate response to intranasal corticosteroids.

Sanofi (SNY) Looks Good: Stock Adds 6.2% in Session

by Zacks Equity Research

Sanofi (SNY) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Neena Mishra headshot

Why Biotech ETFs are Surging to New Highs

by Neena Mishra

increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

Sweta Killa headshot

Biotech ETFs Hit New Highs on Deal Activities

by Sweta Killa

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Kinjel Shah headshot

Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms

by Kinjel Shah

Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.

Week Begins with Biotech Mergers

by Zacks Equity Research

Week Begins with Biotech Mergers

Mark Vickery headshot

Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

by Mark Vickery

Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).

Bristol-Myers' (BMY) Lymphoma Drug Meets Goals in Key Study

by Zacks Equity Research

Bristol-Myers' (BMY) TRANSCEND NHL 001 study on CAR T-cell therapy drug meets endpoints.

Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar

by Zacks Equity Research

FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ

by Kinjel Shah

The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.

AstraZeneca's Lynparza Gets China Nod in First-Line Setting

by Zacks Equity Research

AstraZeneca's (AZN) Lynparza receives approval in China for first-line maintenance treatment of advanced ovarian cancer with BRCA-mutation.